Noonan syndrome (NS) is a relatively common congenital genetic disorder with an estimated prevalence of 1 in 1000 to 1 in 2500 live births. 1 Characteristic findings include distinctive facial features, short stature, chest deformity, and congenital heart disease. It is an autosomal dominant disorder with complete penetrance but variable expressivity. Until recently, diagnosis was based solely on clinical findings, but genetic mutations are identifiable in ϳ61% of the patients. Because of the difficulty in establishing a diagnosis of NS, the Noonan Syndrome Support Group coordinated a meeting of health care providers with expertise in various aspects of the disorder with the aim of developing guidelines for its diagnosis and management. This report is the result of those efforts and is intended to provide the pediatrician with key clinical features of NS, to provide an update of currently understood genetic causes, and to present management recommendations (Table 1) .
A description of the meeting methodology is provided in Supplemental Information.
HISTORY OF NS
In 1962, Jacqueline Noonan, a pediatric cardiologist, identified 9 patients whose faces were remarkably similar and who, in addition, had short stature, significant chest deformities, and pulmonary stenosis. 1 In 1968 Dr Noonan published a case series with these 9 plus an additional 10 patients. 2 The eponym "Noonan syndrome" was adopted in recognition of Dr Noonan, because she was the first to indicate that this condition occurred in both genders, was associated with normal chromosomes, included congenital heart defects, and could be familial. 3 
CLINICAL DESCRIPTION AND DIFFERENTIAL DIAGNOSIS
Facial and musculoskeletal features most often lead to the diagnosis of NS. The facial appearance is most characteristic in infancy (Fig 1) and early-tomiddle childhood and becomes more subtle in adulthood 4 (Fig 1B) . In the newborn infant with NS, the head is large with a small face tucked beneath a large cranium, a tall forehead, and narrowing at the temples. The eyes are wide-spaced and prominent with epicanthal folds, ptosis, and horizontal or down-slanting palpebral fissures (95%). There may be telecanthus as well as hypertelorism. The nose is short and broad with a depressed root and full tip. The ears are low-set, are posteriorly rotated, and have an oval shape and thickening of the helix (90%). The upper lip is distinctive with a deeply grooved philtrum with high, wide peaks to the vermillion of the upper lip (95%), and full lips. Generally, the neck is short with excess skin and a low posterior hairline (55%). In middle-to-late childhood, facial appearance often lacks expression and resembles the face of an individual with a myopathy. By adolescence, face shape is an inverted triangle, wide at the forehead and tapered to a pointed chin. Eyes are less prominent. Features are sharper. There is a narrow nasal root with a thin bridge. The neck is longer, accentuating skin webbing or prominence of the trapezius muscle. The adult face may be quite unremarkable, although the same individual may have had more obvious features as an infant. Some adults, however, have typical features including ptosis, wide-spaced eyes, low-set ears with posterior rotation and thickened helix, and broad or webbed neck. In the older adult, nasolabial folds are more prominent than one would expect for that person's age, and the skin appears transparent and thin.
Hair may be wispy in the toddler, whereas it is often curly or wooly in the older child and adolescent. Regardless of age, eyes are frequently pale blue or blue-green and much lighter in color than expected for family background.
A characteristic pectus deformity of the chest with pectus carinatum superiorly and pectus excavatum inferiorly is seen in most individuals. Also, nipples are wide-spaced and low-set, and rounded shoulders are common. 5 Scoliosis is reported in 10% to 15%. 6 Other less common spinal abnormalities include kyphosis, spina bifida, vertebral and rib abnormalities, and genu valgum. Talipes equinovarus is described in 10% to 15%, other joint contractures in 4%, radio-ulnar synostosis in 2%, and cervical spine fusion in 2%. Abnormal forearm carrying angles (cubitus valgus) are found in more than half the males (10 -11°) and females (14 -15°). 7 Hyperextensibility is common. 7 Because of differences in prognosis, recurrence concerns, and treatment, accurate diagnosis is essential. There are several disorders with significant phenotypic overlap with NS, such as Turner syndrome (Table 2) . [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] For many years, before our understanding of their underlying genetic causes, cardiofaciocutaneous (CFC) syndrome and Costello syndrome were often confused for NS, particularly in the newborn period. Therefore, it was not surprising that they, like NS, were found to be caused by mutations in genes of the Ras/MAPK (mitogen-activated protein kinase) pathway. Other disorders with significant phenotypic overlap with NS include neurofibromatosis type 1, LEOPARD (lentigines, electrocardiographic anomalies, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, and deafness) syndrome, Aarskog syndrome, fetal alcohol syndrome, mosaic trisomy 22, and Baraitser-Winter syndrome. Molecular should be individualized according to the specific disorder(s) present Some will require treatment such as balloon valvuloplasty or surgery; long-term reevaluation of these patients after treatment is essential (specifically, after successful cardiac surgery, cardiac care should not be discontinued) Individuals without heart disease on their initial evaluation should have cardiac reevaluation every 5 y Adults should not discontinue periodic cardiac evaluations even if their evaluations in childhood or adolescence were normal; unexpected cardiac findings can occur at any point in time Growth and endocrine issues
Children should be weighed and measured regularly by the primary care provider, and the data should be plotted on appropriate growth charts (thrice yearly for the first 3 y of life and yearly thereafter) Children with evidence of growth failure (growth deceleration, height less than Ϫ2 SDs, or height inappropriate for genetic background) that cannot be explained by a comorbidity should be monitored more often, have nutrition optimized, have baseline laboratory tests run, and/or be referred to a pediatric endocrinologist Thyroid-function tests and antibodies should be obtained from any child with a goiter and/or symptoms of hypothyroidism (fatigue, constipation, poor growth, etc) Children with evidence of delayed puberty (no breast development in girls by the age of 13 y, no testicular enlargement in boys by 14 y of age) should be referred to a pediatric endocrinologist Therapeutic interventions as indicated (GH for growth failure, thyroid hormone replacement for hypothyroidism, estrogen or testosterone for pubertal delay) Renal A discussion of scoring systems as algorithms of diagnostic criteria is provided in Supplemental Information. 7, 18, 19 
HISTORY OF MOLECULAR GENETIC TESTING AND GENETIC RESEARCH
In 1994, linkage analysis of a large family inheriting NS established definitive linkage to the first NS locus, defined as chromosomal bands 12q22-qter and named NS1. 19, 20 Genetic heterogeneity was subsequently established.
In 2001, Tartaglia and co-workers 21 identified missense mutations in the protein tyrosine phosphatase nonreceptor type 11 gene (PTPN11) as the first molecular causes of NS. This discovery was enabled by the observations that PTPN11 resided within the NS1 critical region and that studies with a mouse model of PTPN11 deficiency revealed that its protein product, SHP-2, was critical for the embryologic development of the semilunar cardiac valves. 22 Because pulmonary valve stenosis (PVS) is a prominent 
Genetic Testing for NS
The currently available commercial tests use different technologies (dideoxynucleotide sequencing, denaturing high-performance liquid chromatography, and oligonucleotidebased microarray sequencing) that fundamentally are based on the presence of missense or small insertions/ deletions in the coding regions and flanking intron boundaries of genes that cause NS. Although gross chromosomal abnormalities (interstitial deletions, duplications, and balanced translocations) have rarely been identified in patients with phenotypes that closely resembled (or were) NS, [36] [37] [38] [39] [40] [41] routine karyotyping or copy-number analysis is not recommended at this time for typical NS cases. It may be considered for atypical cases or when there is particularly severe neurocognitive involvement. There is currently no information concerning the number of cases, if any, that harbor more than 1 mutation for NS because all studies took a sequential genotyping approach. Because 1 center recently introduced the use of microarray-based sequencing in which all relevant genes are analyzed in parallel, it will be of interest to discover whether multiple hits are observed in some subset of patients with NS.
Postnatal Mutation Testing for NS
A suggested algorithm for individual genotyping is shown in Table 1 . The rationale for this algorithm and a discussion of prenatal mutation testing in NS is provided in Supplemental Information [56] [57] [58] ). PTPN11 mutations have been consistently associated with the presence of a pectus deformity, easy bruising, the characteristic facial appearance, and short stature. 49, 50, 59 Children with SOS1-associated NS are more likely to have CFC syndrome-like skin findings (keratosis pilaris, sparse hair, curly hair, sparse eyebrows) 53 and less likely to have short stature 53 or impaired cognitive functioning. 53, 60 Patients with NS caused by missense mutations in PTPN11 are more likely to have PVS and atrial septal defects (ASDs) and less likely to have hypertrophic cardiomyopathy (HCM) than people with NS without a PTPN11 mutation. 21, 42, 49, 50 Those with a pathogenic SOS1 mutation are more likely to have PVS than those with NS who have neither an SOS1 nor a PTPN11 mutation. 33 It is remarkable that 80% to 95% of children with RAF1 mutations have HCM. 31, 32 Pa- tients with the SHOC2 S2G mutation have a distinctive phenotype, initially termed Noonan-like syndrome, with loose anagen hair. 61 In addition to the hair findings, the phenotype may include mitral valve and cardiac septal defects, GH deficiency, ectodermal abnormalities with darkly pigmented ichthyotic skin, hypernasal voice, and developmental issues with hyperactivity. 34 In a study of 45 patients with NS, both bleeding diathesis and juvenile myelomonocytic leukemia were found exclusively in patients with specific PTPN11 mutations. 49 Familial cases of NS are more likely than sporadic cases to be caused by a PTPN11 mutation. 42 NS attributable to KRAS mutations seems to confer a more severe phenotype with more significant learning issues and developmental delays. 50 
GENOTYPE/PHENOTYPE CORRELATIONS

CARDIOVASCULAR ISSUES
More than 80% of patients with NS have an abnormality of the cardiovascular system. 7,62-64 PVS is the most common. The valve may be dysplastic in 25% to 35% of those with PVS [64] [65] [66] and is often associated with an ASD. Isolated ASDs and partial atrioventricular canal defects are also relatively common. A broad spectrum of cardiac abnormalities has been reported, as noted in Table 5 . Approximately 50% of patients with NS have an unusual electrocardiographic pattern characterized by left-axis deviation, an abnormal R/S ratio over the left precordial leads, and an abnormal Q wave. 67 Many patients have mild PVS that requires only periodic reevaluation. If the PVS is or becomes clinically significant, initial treatment is usually pulmonary balloon valvuloplasty, but it may be unsuccessful if the valve is dysplastic. With severe dysplasia, a pulmonary valvectomy or pulmonary homograft may be needed in childhood. The other cardiac defects can be treated in the standard ways.
HCM is present in ϳ20% of patients with NS overall but is particularly frequent with RAF1 mutations, 31, 32 and it is variable in severity and natural history. In some infants with HCM the condition resolves, whereas in others it becomes rapidly progressive and may have a fatal outcome. Others develop HCM after infancy. The course may be stable or progressive, or it may improve. Management is similar to that for any patient with HCM and may include the use of ␤-blocker medications or surgical myomectomy to reduce outflow obstruction. 62 It is important for adults with NS to have lifetime cardiac follow-up. Leftsided obstructive lesions may develop in adulthood. 68 Pulmonary valve insufficiency and right ventricular dysfunction are potential problems after earlier pulmonary valve surgery. Cardiac arrhythmias have been rare in the limited reports available about long-term follow-up of adults. 6,69
GROWTH AND ENDOCRINE ISSUES Growth
Approximately 50% to 70% of individuals with NS have short stature. 7, 70, 71 Although short stature is a main characteristic of this condition, some individuals will have normal growth and stature. Birth weight and length are typically normal, but there is a sub- Coronary artery abnormalities Coarctation of aorta sequent deceleration of height and weight to the third centile or less. The mean delay of bone age is ϳ2 years. 7, 72 NS-specific growth charts have been published. 72, 73 Mean adult heights of European individuals with NS have been reported for women as ϳ153.0 cm and for men as 162.5 and 169.8 cm. 6, 72 The mean adult height of North American individuals is less than the third centile in 54.5% of women (Ͻ151 cm) and 38% of men (Ͻ163.2 cm). 74, 75 A higher prevalence of short stature has been found in PTPN11 mutation-positive subjects than in mutation-negative subjects, and a lower prevalence of short stature has been described for those with SOS1-associated NS. 50, 51 Reports of GH-secretory dynamics have been inconsistent and are likely a reflection of the genotypic heterogeneity of NS. There have been reports of GH deficiency (45% [n ϭ 150] 96 37% [n ϭ 27] 77 ), neurosecretory dysfunction, [78] [79] [80] and completely normal GH secretion. 81, 82 Insulin-like growth factor 1 levels are frequently low and were significantly lower in the PTPN11 mutation-positive than mutationnegative patients. [81] [82] [83] Until recently, most experience with GH in NS has been reported in studies that involved small numbers of patients with varied enrollment ages, treatment durations, doses, and responses.
These studies resulted in improved growth velocity without significant adverse effects. [78] [79] [80] [84] [85] [86] Although most studies have excluded patients with HCM, left ventricular wall thickness remained normal when prospectively measured in patients with NS on GH. [76] [77] [78] In addition, among the combined 889 patients from 6 articles that reported adult-height outcomes in patients with NS on GH, 84, [88] [89] [90] [91] [92] there were only 5 reported cardiac events (2 mild progressions of PVS, 1 HCM, 1 increased biventricular hypertrophy, and 1 cardiac decompensation).
The efficacy of GH in NS can be assessed by considering adult-height data (Table 6 ). 84, [88] [89] [90] [91] Although different parameters were reported in these studies (ie, median versus mean values, height SD scores based on population standards versus the NSspecific standards, varied doses, etc), it seems that improved outcomes (⌬ height SD score: 1.3-1.7; mean height gain: 9.5-13 cm for boys and 9.0 -9.8 cm for girls 89, 90, 92 ) occur with earlier initiation and longer duration of GH therapy, as has been demonstrated for other conditions such as Turner syndrome. 93, 94 Initial short-term data have suggested that PTPN11-positive patients responded "less efficiently" to GH than did the PTPN11-negative patients. 48 In contrast, longer-term data from comparisons of adult heights for those treated with GH among those who were PTPN11 mutation-positive with those who were mutation-negative revealed no difference in outcome. 90 Additional studies may clarify the role of the different RAS/MAPK pathway aberrations in growth and GH responsiveness.
Other Endocrine and Autoimmune Issues
Puberty is typically, but not universally, delayed for both boys and girls with NS and is characterized by a diminished pubertal growth spurt. 72 The mean age of pubertal onset is 13.5 to 14.5 years in boys and 13 to 14 years in girls. Puberty may progress with a rapid tempo (Ͻ2 years). 92 Pubertal induction may be instituted (with careful consideration of timing for optimal height potential) for no secondary sexual characteristics in boys at 14 years (testosterone induction) and girls at 13 years (estrogen induction).
Thyroid antibodies are commonly found, but hypothyroidism is likely no more common in those with NS than in the general population. 7, [95] [96] [97] There have been case reports of the occurrence of other autoimmune conditions, such as systemic lupus erythematosus and celiac disease, but their frequency is unknown. [98] [99] [100] 
RENAL AND GENITOURINARY ISSUES
Renal anomalies occur in 10% to 11% of those with NS and are usually of little significance. 7, 98, 99 Solitary kidney, renal pelvis dilation, and duplicated collecting system have been reported. Cryptorchidism occurs in up to 80% of boys, and surgical orchiopexy is required. Recent evidence suggests sertoli cell dysfunction 101 rather than cryptorchidism as the etiology of male gonadal dysfunction. Fertility does not seem to be affected in women.
HEMATOLOGY AND ONCOLOGY ISSUES
Disordered bleeding has been reported for 30% to 65% of individuals with NS. 7, 102 Although the symptoms are often mild, such as excessive bruising, epistaxis, or menorrhagia, bleeding with surgical procedures can be significant. A number of coagulation-factor deficiencies (isolated and combined), thrombocytopenia, and platelet dysfunction have been described. Elevation of the activated partial thromboplastin time is frequent. Approximately 25% of individuals with NS have partial factor XI deficiency. [102] [103] [104] [105] [106] [107] The bleeding symptoms do not correlate well with the degree of deficiency. A number of other coagulation factors can be depressed, and low factor XII and factor VIII activity are the next most frequent depressions. [105] [106] [107] It is important to note that although factor XII deficiency can prolong the activated partial thromboplastin time, it does not result in clinical bleeding. Low factor VIII levels can be seen with von Willebrand disease, which is a common bleeding disorder in the general population; although both low factor VIII and von Willebrand factor have been reported in NS, an accurate estimate of the prevalence of von Willebrand disease in patients with NS has not yet been determined. [105] [106] [107] Less commonly, factor IX and factor II have also been reported to be deficient in patients with NS and can contribute to bleeding risk. 105, 108 Both thrombocytopenia and platelet dysfunction have been described in patients with NS. The etiology of the thrombocytopenia is probably multifactorial and can be associated with a defect in platelet production caused by a decrease in megakaryocytes. 108 Splenomegaly may also cause mild-tomoderate thrombocytopenia and is found by ultrasound in up to 52% of patients with NS. 109 Splenomegaly may be isolated or associated with hepatomegaly. In some patients, hepatosplenomegaly or splenomegaly may be caused by NS/myeloproliferative disorder (MPD).
NS/MPD is a condition seen in infants with NS that is characterized by leukocytosis with monocytosis, thrombocytopenia, and hepatosplenomegaly. Although the clinical picture of NS/MPD resembles that of juvenile myelomonocytic leukemia, infants with NS/MPD seem to have a favorable prognosis. Although some infants with NS/MPD have been reported to develop aggressive leukemia, the majority with this condition present in the first few months of life and will remain stable or improve by 1 year of age without specific therapy. 110, 111 Despite the role of somatic PTPN11 and KRAS mutations in the development of malignancies, the incidence of cancer in older children and adults with NS has not been shown to be increased over that of the general population. 6, 112 However, additional studies are needed to accurately assess the risk of malignancy in individuals with NS.
NEUROLOGIC, COGNITIVE, AND BEHAVIORAL ISSUES
The neurologic, cognitive, and behavioral aspects of individuals with NS are poorly understood and extremely variable. There is an increased incidence of cognitive issues and learning disabilities, an increased incidence of brain abnormalities, and a wide array of other neurologic problems. In a study of 151 subjects with NS, 76% had feeding difficulties, 94% had ocular problems, 50% had hypermobility of joints/hypotonia, 13% had recurrent seizures, 3% had hearing loss, and 3% had peripheral neuropathy. 7 There was also a general delay in the mean age of motor milestones; sitting alone occurred at 10 months, walking occurred at 21 months, and speaking 2-word sentences occurred at 31 months. 7 Another study revealed that 84% had some type of neurologic problem. 113 Structural malformations and deformations of the central nervous system and spinal cord are found at relatively low frequency. The most common defects are Arnold-Chiari malformation type I and hydrocephalus. The mean head circumference is at the 50th percentile; however, some individuals with NS can be microcephalic or macrocephalic. 7 Most people with NS have normal intelligence, but 10% to 40% require special education. 7, 114, 115 Even among those of normal intelligence, IQ has been shown to be 10 points less than unaffected family members or 1 SD below that of the general population. 114 The observed heterogeneity in cognitive abilities in syndromes of the Ras/MAPK signaling cascade including NS can be at least partially ascribed to the individual affected genes and the type of mutation. 116 For example, SOS1 mutations 53, 60, 116 and specific PTPN11 mutations 42, 60, 116, 117 have been associated with no or mild cognitive delays.
Children with NS have a higher rate of clumsiness, poor coordination, stubbornness, and irritability. 118 Bodyimage problems and poor self-esteem, depression, and social inadequacy have been noted to occur in adults with NS. 69 Limited data are available on the psychological and psychiatric characteristics of patients with NS. Psychiatric problems are rarely found, and qualitative data in a study of 112 adults 6 with NS revealed their reporting an inability to fit in but an overall good or satisfactory quality of life. In addition, the majority of adults with NS finished high school and had paying jobs. 6,69
GASTROINTESTINAL AND FEEDING ISSUES
Most infants (75%) with NS have feeding difficulties; poor suck with prolonged feeding time (15%), very poor suck and slow feeding with recurrent vomiting (38%), and severe feeding problems that require tube-feeding for Ն2 weeks (24%) have been described. 6, 7 Investigation of some children with poor feeding has revealed immaturity of gut motility and delayed gastrointestinal motor development. 119 Gastroesophageal reflux is common, and there have been a few reports of malrotation. 109, 120 Typically, the period of failure to thrive is self-limited, although poor weight gain may persist for up to 18 months.
ORAL AND DENTAL ISSUES
Oral findings in patients with NS include a high arched palate (55%-100%), 37, 72, 121 dental malocclusion (50%-67%), 6,120-123 articulation difficulties (72%), 71 and micrognathia (33%-43%). Some individuals with NS develop mandibular cysts, which can mimic cherubism. 124, 125 The pathology of these lesions in individuals with NS is characterized by multinucleated giant cells within a fibrous stroma and is indistinguishable from cherubism. These 2 conditions, however, are genetically distinct; SH3BP2 gene mutations are found in individuals with cherubism, whereas PTPN11 126 and SOS1 127 mutations are found in patients with NS with giant cell lesions.
LYMPHATIC ISSUES
NS is associated with a generalized disorder of lymphatic development, which has manifestations in fetal life through adulthood. 128, 129 The overall incidence of lymphatic manifestations in all age groups of those with NS is unknown, but it is estimated to be ϳ20%. Peripheral lymphedema, the most common lymphatic manifestation, is seen most frequently in young infants. It typically resolves in the first few years. Adolescents and adults can develop peripheral lymphedema. 130 Other types of lymphatic involvement that have been described in patients with NS include hydrops, chylous pleural effusions, chylothorax, pulmonary lymphangiectasis, intestinal lymphangiectasia, hypoplastic leg lymphatics, anomalous lymphatic vessels in the thoracic cage and aplasia or absence of the thoracic duct, hypoplastic inguinal and iliac lymphatic vessels, and testicular lymphangiectasis. Management of these conditions can be difficult. 131, 132 A discussion of malignant hyperthermia in patients with NS is provided in Supplemental Information. [133] [134] [135] [136] [137] Table 7 lists support organizations that may serve as additional resources regarding NS.
CONCLUSIONS
These guidelines were developed from an interdisciplinary meeting of experts involved in the care of and research on individuals with NS. Our goal was to provide the pediatrician with new information and accrued experience to promote the correct diagnosis and best care of those with NS. Recognizing that NS is a clinically and genetically heterogeneous condition characterized by congenital heart disease, distinct facial features, short stature, and many other potential comorbidities, patients do require multidisciplinary evaluations and regular follow-up care for their identified issues. Certainly, many questions remain unanswered regarding the optimal care of these individuals not only in childhood but throughout adulthood. Therefore, it is important to recognize that the recommendations in this report are based on the authors' best judgments and the current available medical knowledge.
ACKNOWLEDGMENTS
This article was developed through a conference organized by the Noonan Syndrome Support Group. The funding for the conference was provided by an independent medical education grant from Novo Nordisk, Inc to the Noonan Syndrome Support Group. Representatives from Novo Nordisk, Inc did not participate in any scientific deliberations, did not contribute to the content of this report, and did not review or comment on this report before publication.
We thank Dr Mignon Loh for helpful discussion about NS/MPD. 
